Where the research is focused
Research in this area asks how specific peptide signals interact with the body’s natural systems. The aim is to understand mechanisms, identify meaningful outcomes and test questions carefully — not to assume that a promising pathway is already a useful treatment.
What current evidence can tell us
MOTS-c and humanin are examples of MDPs studied in laboratory research and human observational or exercise settings. A 2026 systematic review of nine studies found that peptide levels often trended upward after exercise, but study methods and participants varied and human evidence remains limited. The results help map biology; they do not show that taking a peptide improves energy.
A peptide’s biological role, a result in a cell or animal model, and a proven benefit in people are different levels of evidence. Human safety and effectiveness require suitable clinical studies and regulatory assessment.
MOTS-c · SS-31
This page introduces published research. It is not medical advice, a treatment recommendation or an invitation to use research compounds. In Australia, the TGA explains that a “research use only” label does not by itself change the regulatory requirements for a therapeutic peptide product. Read the TGA’s overview.